Google’s $20 million investment to support the development of artificial intelligence

According to Google’s latest report, more than 2 million researchers in 190 countries are now using AlphaFold to help accelerate the fight against malaria and pave the way for treatments. New Parkinson’s use.

AlphaFold is an artificial intelligence-based bioinformatics tool developed by DeepMind, a subsidiary of Google, and the European Bioinformatics Institute EMBL-EBI. This tool is able to predict the three-dimensional structure of proteins with high accuracy. This ability helps biologists to have a better and more accurate understanding of the function of proteins in the human body and other living organisms. Determining the structure of proteins using sequence has been one of the big challenges in biology, and AlphaFold has been able to overcome this big challenge.

That being said, AI has enabled our progress in a wide range of scientific fields, from hydrology to neuroscience to climate.

But for AI to deliver the next generation of scientific breakthroughs, scientists need funding, computing power, interdisciplinary expertise, and access to infrastructure, including essential datasets, such as the protein data bank that powers AlphaFold.

For this reason, Google has set aside a budget of 20 million dollars to support academic and non-profit organizations around the world; Organizations that use artificial intelligence to address more complex problems.

Google said in its announcement that “we will use all our capacity to identify and announce the names of related organizations.”

It should be noted that these figures are separate from the 200 million dollars that Google has provided to organizations that have used artificial intelligence to accelerate their scientific work in the last 5 years.

“Time and time again, funding, technology and collaboration have come together to drive scientific discovery,” Google continued in the announcement. We hope that this new funding will help grow more Nobel-level achievements that will improve the lives of millions of people, and that other philanthropic, public and private investors will join us in investing in meaningful, long-term outcomes.”